(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Olfaction Disorders D000857 17 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Body Weight D001835 333 associated lipids
Brain Diseases D001927 27 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Rasch MR et al. Chains, sheets, and droplets: assemblies of hydrophobic gold nanocrystals with saturated phosphatidylcholine lipid and squalene. 2012 Langmuir pmid:23033891
Singh M et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. 2012 Hum Vaccin Immunother pmid:22832252
Vesikari T et al. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. 2012 Hum Vaccin Immunother pmid:22906943
Vesikari T et al. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. 2012 Hum Vaccin Immunother pmid:22777094
Bencharitiwong R et al. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. 2012 Hum Vaccin Immunother pmid:22777093
Faenzi E et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. 2012 Vaccine pmid:22521851
Hatz C et al. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. 2012 Vaccine pmid:22626675
Hwang SM et al. Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. 2012 Jpn. J. Infect. Dis. pmid:22627298
Siegrist CA et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. 2012 Antivir. Ther. (Lond.) pmid:22544169
Yang M et al. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. 2012 Int. Immunopharmacol. pmid:22595192
Cabrera-Vique C et al. Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. 2012 Nutr. Rev. pmid:22537213
Stella B et al. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. 2012 Eur J Pharm Biopharm pmid:22008147
Ambrose CS and Belshe RB Influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22276839
Heikkinen T and Heinonen S Influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22276840
Gasparini R et al. Aflunov(®): a prepandemic influenza vaccine. 2012 Expert Rev Vaccines pmid:22309663
Spanova M et al. Influence of squalene on lipid particle/droplet and membrane organization in the yeast Saccharomyces cerevisiae. 2012 Biochim. Biophys. Acta pmid:22342273
Palma P et al. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. 2012 Biologicals pmid:22261282
Heikkinen T et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. 2012 Am. J. Obstet. Gynecol. pmid:22939717
Mannino S et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. 2012 Am. J. Epidemiol. pmid:22940713
Klucker MF et al. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. 2012 J Pharm Sci pmid:22941944
Vishnubhatla S et al. Contact lenses and the rate of evaporation measured in vitro; the influence of wear, squalene and wax. 2012 Cont Lens Anterior Eye pmid:22906863
Hoshino T et al. Lanosterol biosynthesis: the critical role of the methyl-29 group of 2,3-oxidosqualene for the correct folding of this substrate and for the construction of the five-membered D ring. 2012 Chemistry pmid:22933236
Wilson KR et al. The statistical evolution of multiple generations of oxidation products in the photochemical aging of chemically reduced organic aerosol. 2012 Phys Chem Chem Phys pmid:22158973
Xue Z et al. Divergent evolution of oxidosqualene cyclases in plants. 2012 New Phytol. pmid:22150097
Oral E et al. A new mechanism of oxidation in ultrahigh molecular weight polyethylene caused by squalene absorption. 2012 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:22190411
Sancho A et al. More on influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22738111
Yang P et al. Two concise enantioselective total syntheses of (-)-glabrescol implicate alternative biosynthetic pathways starting from squalene. 2012 Org. Lett. pmid:22817611
Ramírez-Torres A et al. Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. 2012 J Proteomics pmid:22796066
Surls J et al. Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. 2012 PLoS ONE pmid:22723880
Girod A et al. Composition of fingermark residue: a qualitative and quantitative review. 2012 Forensic Sci. Int. pmid:22727572
Sarpietro MG et al. Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. 2012 Int J Pharm pmid:22728161
Wu S et al. Engineering triterpene metabolism in tobacco. 2012 Planta pmid:22729821
Langley JM et al. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. 2012 Pediatr. Infect. Dis. J. pmid:22801094
Block SL et al. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. 2012 Pediatr. Infect. Dis. J. pmid:22481427
Lai RP et al. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 2012 PLoS ONE pmid:22509385
Marinaro M et al. A caprine herpesvirus 1 vaccine adjuvanted with MF59â„¢ protects against vaginal infection and interferes with the establishment of latency in goats. 2012 PLoS ONE pmid:22511971
Calmy A et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. 2012 HIV Med. pmid:22093373
Dell'Era L et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. 2012 Vaccine pmid:22138210
Allain V et al. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. 2012 Nucleic Acids Res. pmid:22075995
Cosco D et al. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. 2012 Int J Nanomedicine pmid:22679366
O'Hagan DT et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. 2012 Vaccine pmid:22682289
Lokvam J and Fine PV An oxidized squalene derivative from Protium subserratum Engl. (Engl.) growing in Peru. 2012 Molecules pmid:22706374
Yu S et al. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. 2012 Vaccine pmid:22709954
Granados-Principal S et al. Squalene ameliorates atherosclerotic lesions through the reduction of CD36 scavenger receptor expression in macrophages. 2012 Mol Nutr Food Res pmid:22648620
Song JY et al. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. 2012 Clin. Vaccine Immunol. pmid:22379067
Caproni E et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. 2012 J. Immunol. pmid:22351935
Kim SK and Karadeniz F Biological importance and applications of squalene and squalane. 2012 Adv. Food Nutr. Res. pmid:22361190
Dey AK et al. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 2012 Vaccine pmid:22366638
Garçon N et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. 2012 Expert Rev Vaccines pmid:22380826
Ramírez-Torres A et al. Proteomics and gene expression analyses of mitochondria from squalene-treated apoE-deficient mice identify short-chain specific acyl-CoA dehydrogenase changes associated with fatty liver amelioration. 2012 J Proteomics pmid:22402057
Tronchoni J et al. Lipid composition of wine strains of Saccharomyces kudriavzevii and Saccharomyces cerevisiae grown at low temperature. 2012 Int. J. Food Microbiol. pmid:22405355
Fox CB et al. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. 2012 AAPS PharmSciTech pmid:22415641
Nassim C et al. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. 2012 Pediatr. Infect. Dis. J. pmid:22418661
Fox CB et al. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. 2012 Clin. Vaccine Immunol. pmid:22896687
Reynales H et al. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. 2012 Vaccine pmid:22902681
Peric M et al. Electron paramagnetic resonance line shifts and line shape changes due to heisenberg spin exchange and dipole-dipole interactions of nitroxide free radicals in liquids 8. Further experimental and theoretical efforts to separate the effects of the two interactions. 2012 J Phys Chem A pmid:22288424
Liu Y et al. [Researches on influence of squalene synthase gene polymorphism on catalytic efficiency of its encode enzyme in Glycyrrhiza uralensis]. 2012 Zhongguo Zhong Yao Za Zhi pmid:23627178
Bihari I et al. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. 2012 Clin. Vaccine Immunol. pmid:23081815
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Liu YT et al. Protein engineering of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase into parkeol synthase. 2012 Org. Lett. pmid:23043506
Ta MT et al. Accumulation of squalene is associated with the clustering of lipid droplets. 2012 FEBS J. pmid:23013491
Nielsen AB et al. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. 2012 Vaccine pmid:23036498
Binks BP et al. How membrane permeation is affected by donor delivery solvent. 2012 Phys Chem Chem Phys pmid:23073464
Yockel S and Schatz GC Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. 2012 Top Curr Chem pmid:21506003
Nguyen HT et al. Molecular characterization of Glycine max squalene synthase genes in seed phytosterol biosynthesis. 2013 Plant Physiol. Biochem. pmid:24036394
Borchman D et al. Confirmation of the presence of squalene in human eyelid lipid by heteronuclear single quantum correlation spectroscopy. 2013 Lipids pmid:24081494
Guan X et al. Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease. 2013 Hum Vaccin Immunother pmid:23732905
Goff PH et al. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. 2013 PLoS ONE pmid:24223176
Lepeltier E et al. Self-assembly of squalene-based nucleolipids: relating the chemical structure of the bioconjugates to the architecture of the nanoparticles. 2013 Langmuir pmid:24219056
Vono M et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24324152
Pannkuk EL et al. Sebaceous lipid profiling of bat integumentary tissues: quantitative analysis of free Fatty acids, monoacylglycerides, squalene, and sterols. 2013 Chem. Biodivers. pmid:24327437
Tegenge MA and Mitkus RJ A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines. 2013 J Pharmacokinet Pharmacodyn pmid:23912214
Moro ML et al. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. 2013 Vaccine pmid:22885015
Ruiz-Aragón J et al. [Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature]. 2013 An Pediatr (Barc) pmid:23490433
Yüzbaşıoğlu D et al. Genotoxicity assessment of vaccine adjuvant squalene. 2013 Food Chem. Toxicol. pmid:23454296
Malmierca MG et al. Relevance of trichothecenes in fungal physiology: disruption of tri5 in Trichoderma arundinaceum. 2013 Fungal Genet. Biol. pmid:23454546
Rodríguez-López J et al. Epoxide-opening cascades triggered by a Nicholas reaction: total synthesis of teurilene. 2013 Angew. Chem. Int. Ed. Engl. pmid:23436322
Skowronski DM et al. Re: "effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy". 2013 Am. J. Epidemiol. pmid:23436898
Hosogaya N et al. The heme-binding protein Dap1 links iron homeostasis to azole resistance via the P450 protein Erg11 in Candida glabrata. 2013 FEMS Yeast Res. pmid:23496820
Rappuoli R Vaccine adjuvants: the future is bright. Interview by Jenaid Rees. 2013 Expert Rev Vaccines pmid:23829664
Trung Bui D et al. Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy. 2013 Biomacromolecules pmid:23829862
Bruun Laursen A [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene]. 2013 Ugeskr. Laeg. pmid:23833781
Mølbak K [Squalene unlikely sinner]. 2013 Ugeskr. Laeg. pmid:23833782
Gefenaite G et al. Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination. 2013 PLoS ONE pmid:23840413
Fox CB and Haensler J An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. 2013 Expert Rev Vaccines pmid:23885820
Caron J et al. Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene. 2013 Adv Healthc Mater pmid:23213041
Rubinstein F et al. Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. 2013 BMJ pmid:23381200
Puleston R et al. Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine. 2013 PLoS ONE pmid:23372640
Kabuto H et al. Effects of squalene/squalane on dopamine levels, antioxidant enzyme activity, and fatty acid composition in the striatum of Parkinson's disease mouse model. 2013 J Oleo Sci pmid:23357814
Son J et al. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients. 2013 Clin. Exp. Nephrol. pmid:22990301
Durier C et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. 2013 AIDS pmid:23018437
Hong WK et al. Characterization of a squalene synthase from the thraustochytrid microalga Aurantiochytrium sp. KRS101. 2013 J. Microbiol. Biotechnol. pmid:23676912
Yoshimura T et al. Solution properties and emulsification properties of amino acid-based gemini surfactants derived from cysteine. 2013 J Oleo Sci pmid:23985487
Fu D et al. ATR-IR study of ozone initiated heterogeneous oxidation of squalene in an indoor environment. 2013 Environ. Sci. Technol. pmid:23957297
Van Buynder PG et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. 2013 Vaccine pmid:23933368
Vinay TN et al. Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). 2013 Vaccine pmid:23896420
Ito R et al. Effect of cation-π interactions and steric bulk on the catalytic action of oxidosqualene cyclase: a case study of Phe728 of β-amyrin synthase from Euphorbia tirucalli L. 2013 Chemistry pmid:24203491
Rigane G et al. Effect of storage on refined olive oil composition: stabilization by addition of chlorophyll pigments and squalene. 2013 J Oleo Sci pmid:24292349
Esche R et al. Online LC-GC-based analysis of minor lipids in various tree nuts and peanuts. 2013 J. Agric. Food Chem. pmid:24251555
Ueda D et al. Cyclization of squalene from both termini: identification of an onoceroid synthase and enzymatic synthesis of ambrein. 2013 J. Am. Chem. Soc. pmid:24274794